Jan 28, 2021 7:00am EST Can-Fite’s NASH Indication Highlighted in Webinar by KOL Dr. Harrison: “Namodenoson May Have Big Impact on NASH”
Jan 08, 2021 7:00am EST Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers
Dec 15, 2020 7:00am EST Can-Fite Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs
Dec 03, 2020 7:00am EST Can-Fite to Present at Benzinga Global Small Cap Conference on December 8, 2020
Nov 30, 2020 7:00am EST Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update
Nov 24, 2020 7:00am EST Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting’ in the NASH Category of the American Association of Liver Diseases (AASLD)
Nov 23, 2020 7:00am EST Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET
Nov 16, 2020 7:00am EST Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference
Nov 09, 2020 7:00am EST Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020
